Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

During IDWeek 2024 in the US, novel antimicrobials in the development pipeline that are poised to make a difference were ...

Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

Zymeworks has dosed the first subject in a Phase I trial of ZW171 to treat ovarian cancer, non-small cell lung cancer and ...